Thermo Fisher Opens Flagship United States Center in Philadelphia to Accelerate Cell & Gene Therapy Development

  New state-of-the-art facility in Philadelphia provides integrated lab and collaboration space along with tailored guidance to help move advanced th...

November 19, 2025 | Wednesday | News
Emerging EMEA: A Vital and Evolving Landscape for Biopharma Strategy, Offering a Blueprint for Agile Market Access and Global Patient Reach

  In these diverse and dynamic markets, adaptation is not a strategy; it is a prerequisite for thriving. Success requires a fundamental shift in mind...

November 19, 2025 | Wednesday | Opinion
PrognomiQ Launches ProVue Lung, a Blood-Based Test Designed for Earlier Lung Cancer Detection

Initial commercial availability begins through an Early Experience Program with Penn Highlands Healthcare and Allegheny Health Network –  Pr...

November 19, 2025 | Wednesday | News
Johnson & Johnson to Acquire Halda in $3.05 Billion Deal to Expand First-in-Class RIPTAC™ Therapeutic Platform

Halda to be acquired by Johnson & Johnson for $3.05 billion in cash Halda recently presented positive Phase 1/2 data for HLD-0915 in metastatic ca...

November 18, 2025 | Tuesday | News
Parse Biosciences’ GigaLab to Power 5 Million–TCR Mapping Effort With Third Rock Ventures

Third Rock Ventures and Parse Biosciences  announced a strategic collaboration to create an unprecedented atlas of 5 million T cell receptors (TCRs)...

November 17, 2025 | Monday | News
Legend Biotech Expands U.S. R&D Footprint With New Philadelphia Innovation Center

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a U.S.-based global leader in cell therapy,  announced the official opening and ribbon c...

November 17, 2025 | Monday | News
Atomic Launches to Bridge the Gap Between Breakthrough MedTech Innovation and Venture-Ready Business

-Atomic launches today as a first-of-its-kind service offering for MedTech startups built to bridge the gap between breakthrough concepts and investor-re...

November 13, 2025 | Thursday | News
March Biosciences Receives FDA RMAT Designation for MB-105 CAR-T in T-Cell Lymphoma

- March Biosciences (March Bio), a clinical stage biotechnology company developing cell therapies for hard-to-treat cancers,  announced that the U.S...

November 12, 2025 | Wednesday | News
Gnome Sciences Identifies Cancer Drug That Prevented ALS in Preclinical Study

Gnome Sciences, a molecular pathology and translational research services company, announced a significant advance in the fight against ALS (amyotrophic ...

November 12, 2025 | Wednesday | News
Vascarta and CUNY Report Preclinical Breakthrough Demonstrating STO-1 Selectively Eliminates Glioblastoma Cells

Vascarta Inc., a healthspan focused, clinical stage biopharmaceutical company advancing safe, patient friendly therapies for pain, inflammation, and, in ...

November 11, 2025 | Tuesday | News
Novartis Opens Carlsbad Radioligand Therapy Manufacturing Site as Part of $23B US Investment Plan

Carlsbad location is company’s third US-based radioligand therapy (RLT) manufacturing site New site expands manufacturing footprint to meet fut...

November 11, 2025 | Tuesday | News
Merck Presents Phase 3 Data Showing Enlicitide Achieved Up to 60% LDL-C Reduction With Placebo-Like Safety

Enlicitide, designed to deliver antibody-like efficacy, has the potential to be the first approved oral PCSK9 inhibitor to lower LDL-C with a safety pr...

November 10, 2025 | Monday | Reports
Cytiva Launches Fibro dT Platform to Accelerate High-Yield mRNA Purification

Fibro dT platform offers a high-capacity solution for mRNA purification with chromatography cycle times under 15 minutes.  Sustainable pe...

November 07, 2025 | Friday | News
Normunity Doses First Patient in Phase 1 Trial of NRM-823, a First-in-Class T Cell Engager

Phase 1a/1b study will evaluate NRM-823 as monotherapy and in combination with immune checkpoint inhibition in patients with locally-advanced or metastat...

November 06, 2025 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close